# A Real-world Study of the Efficacy and Safety of ICIs as First-line Therapy for Advanced Malignancies

> **NCT05862259** · — · RECRUITING · sponsor: **Xinqiao Hospital of Chongqing** · enrollment: 120 (estimated)

## Conditions studied

- Malignant Tumor
- Immunotherapy
- Artificial Intelligence

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05862259
- **Lead sponsor:** Xinqiao Hospital of Chongqing
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-10
- **Primary completion:** 2025-08-10
- **Final completion:** 2025-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05862259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05862259, "A Real-world Study of the Efficacy and Safety of ICIs as First-line Therapy for Advanced Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05862259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*